Female patients suffer from a far greater number of some musculoskeletal (MSK) injuries than do male patients.^[@bibr6-2325967119831061],[@bibr19-2325967119831061],[@bibr26-2325967119831061],[@bibr37-2325967119831061],[@bibr59-2325967119831061]^ They are up to 8 times more likely to experience an anterior cruciate ligament (ACL) tear^[@bibr3-2325967119831061],[@bibr26-2325967119831061]^ and twice as likely to experience an ankle sprain.^[@bibr19-2325967119831061]^ Female patients are also more prone to patellofemoral syndrome, stress fractures, and injuries of the shoulder.^[@bibr6-2325967119831061],[@bibr37-2325967119831061],[@bibr59-2325967119831061]^ While anatomic and biomechanical factors likely contribute to this sex disparity in MSK injuries, there is compelling evidence that female hormones, such as relaxin, estrogen, and progesterone, play a role as well.^[@bibr14-2325967119831061],[@bibr15-2325967119831061],[@bibr21-2325967119831061],[@bibr32-2325967119831061],[@bibr45-2325967119831061]^ This has generated speculation that compounds such as hormonal contraceptives, which change relaxin, estrogen, and progesterone levels, may also influence MSK health.

The ACL is a prime example of a soft tissue susceptible to hormonal influences. Relaxin, best known for its role in loosening the pubic symphysis during pregnancy,^[@bibr60-2325967119831061]^ increases knee laxity in female guinea pigs,^[@bibr16-2325967119831061]^ exhibits collagenolytic effects in human female---but not male---ACL cells,^[@bibr38-2325967119831061]^ and has greater receptor levels in female ACLs than in male ACLs.^[@bibr15-2325967119831061],[@bibr21-2325967119831061]^ Female athletes with elevated relaxin levels are also more likely to tear their ACLs than female athletes with lower circulating levels.^[@bibr14-2325967119831061]^ Estrogen, similar to relaxin, has been shown to promote catabolic processes in ACL cells,^[@bibr29-2325967119831061],[@bibr40-2325967119831061],[@bibr45-2325967119831061]^ decrease ACL strength in a rabbit model,^[@bibr66-2325967119831061]^ and increase ACL laxity in humans.^[@bibr57-2325967119831061]^ In contrast, studies have found that progesterone decreases ACL laxity^[@bibr57-2325967119831061]^ and decreases relaxin-induced collagen degradation.^[@bibr13-2325967119831061],[@bibr29-2325967119831061],[@bibr60-2325967119831061]^

Additional research indicates that other MSK tissues are also susceptible to female hormones. Receptors for relaxin, estrogen, and progesterone have been found on a variety of MSK tissues including the lateral collateral ligament^[@bibr13-2325967119831061]^ and patellar,^[@bibr13-2325967119831061],[@bibr28-2325967119831061]^ Achilles,^[@bibr8-2325967119831061]^ posterior tibial,^[@bibr7-2325967119831061]^ and flexor digitorum longus^[@bibr62-2325967119831061]^ tendons. As in the ACL, relaxin and estrogen have been shown to promote catabolic processes in other MSK tissues,^[@bibr28-2325967119831061]^ with estrogen also up-regulating relaxin receptors in the rat patellar tendon and lateral collateral ligament.^[@bibr13-2325967119831061]^ Because relaxin, estrogen, and progesterone all affect soft tissue and muscle health, different combinations and levels of these hormones could influence MSK injury risk.

Hormonal contraceptives dramatically change levels of relaxin, estrogen, and progesterone and therefore have been theorized to affect MSK function.^[@bibr14-2325967119831061],[@bibr28-2325967119831061]^ Contraceptive formulations may be combined, containing both estrogen and progestin, or contain progestin only. Supplying exogenous hormones inhibits the hypothalamic-pituitary-gonadal axis.^[@bibr30-2325967119831061]^ Thus, the endogenous production of estrogen and progesterone decreases significantly, the cyclic hormonal changes found throughout the normal menstrual cycle are eliminated, and the natural estrogen and progesterone peaks are lost.^[@bibr30-2325967119831061]^ Similarly, hormonal contraceptives alter relaxin production. Relaxin levels change when the contraceptive-induced elimination of normal hormone cycling results in ovulation suppression, thus inhibiting corpus luteum formation.^[@bibr30-2325967119831061]^ Because the corpus luteum is the primary site of relaxin production in nonpregnant female patients, relaxin levels decrease with hormonal contraceptive use.^[@bibr46-2325967119831061]^

Various clinical studies have examined the effects of hormonal contraceptive regimens on MSK function.^[@bibr1-2325967119831061],[@bibr8-2325967119831061],[@bibr9-2325967119831061],[@bibr14-2325967119831061],[@bibr25-2325967119831061],[@bibr35-2325967119831061],[@bibr44-2325967119831061],[@bibr54-2325967119831061],[@bibr58-2325967119831061]^ Yet, very little analysis has been conducted to determine the impact of specific contraceptive formulations on ligaments, tendons, and muscles in vitro and in vivo. Only 1 study has assessed this relationship in an animal model; the authors concluded that contraceptive administration decreases the average stiffness and increases the total energy absorbed before a rupture of the rat ACL.^[@bibr71-2325967119831061]^ Although the available literature examining the effects of hormonal contraceptive use in patient populations is more extensive, very little agreement exists within this body of research. Several studies have argued each side of the debate, leaving it unclear whether hormonal contraceptives are protective, detrimental, or noninfluential with respect to MSK injury risk.^[@bibr1-2325967119831061],[@bibr14-2325967119831061],[@bibr25-2325967119831061],[@bibr35-2325967119831061],[@bibr44-2325967119831061],[@bibr54-2325967119831061],[@bibr58-2325967119831061]^

In this systematic review, studies that evaluated the impact of hormonal contraceptives on soft tissue and muscle health were analyzed to better understand the literature's conflicting findings. We aimed to provide clinically relevant and evidence-based recommendations on the use of hormonal contraceptives in female patients who are at a high risk of experiencing an MSK injury, such as competitive female athletes.

Methods {#section1-2325967119831061}
=======

This systematic review was designed using the Cochrane Collaboration guidelines.^[@bibr34-2325967119831061]^ Literature was only included if the study compared human soft tissue injuries, soft tissue laxity, muscle injuries, or muscle strength in hormonal contraceptive users versus nonusers. Hormonal contraceptives were defined as oral contraceptives (OCs) or hormonal intrauterine devices, implants, or patches. A soft tissue injury was defined as clinically relevant ligament, tendon, or cartilage damage. Soft tissue laxity was defined as the measurement of ligament or tendon laxity, stiffness, or strain under stress. A muscle injury was defined as clinically relevant muscle damage. Muscle strength was defined as the measurement of isometric strength, force output, endurance, peak torque, stretch reflex, or parameters of physical performance.^[‡](#fn10-2325967119831061){ref-type="fn"}^

Two independent reviewers conducted searches in the PubMed, Cochrane, Scopus, CINAHL, and Embase databases. The search parameters included hormonal contraceptive terms combined using the "AND" function with either soft tissue injury/laxity terms or muscle injury/strength terms.

Hormonal contraceptive terms: hormonal contraceptive OR "birth control" OR oral contraceptive OR contraceptive agent OR steroidal contraceptive.Soft tissue injury and laxity terms: ligament injury OR ligament laxity OR ligament rupture OR ligament stiffness OR ligament reconstruction OR ligament elasticity OR anterior tibial displacement OR tendon injury OR tendon laxity OR tendon rupture OR tendon reconstruction OR tendon stiffness OR tendon elasticity OR cartilage injury OR cartilage repair OR cartilage regeneration OR joint laxity OR joint stiffness OR joint dislocation OR musculotendinous stiffness OR musculoskeletal injury OR sports injury OR soft tissue injury OR tendinopathy OR sprain OR cartilage degradation.Muscle injury and strength terms: muscle strength OR muscle stiffness OR muscle force production OR muscle injury OR muscle voluntary contraction.

After compiling search results from all databases, studies were excluded if they were duplicates, if their titles and abstracts did not meet inclusion criteria, or if they were not written in English. Subsequently, studies were excluded if, upon review of the full article, they failed to meet inclusion criteria. Each included study was scored by 2 independent reviewers using the GRADEPro scoring system software.^[@bibr20-2325967119831061]^ A custom template was designed based on the *British Medical Journal Clinical Evidence* GRADE (Grades of Recommendation Assessment, Development and Evaluation) scoring system^[@bibr5-2325967119831061]^ and the GRADEPro guidelines.^[@bibr63-2325967119831061]^ Following these guidelines, each study was evaluated as having very serious, serious, or nonserious flaws in the risk of bias, imprecision, inconsistency, and indirectness categories. Additionally, studies were assessed for effect size, dose response, publication bias, and adjustment for confounders. The findings were entered into the GRADEPro scoring system software, which provided a final GRADE score (*very low*, *low*, *moderate*, or *high*) for each article based on these inputs ([Table 1](#table1-2325967119831061){ref-type="table"}).

###### 

Scoring Results

![](10.1177_2325967119831061-table1)

  Study                                              Risk of Bias   Imprecision   Indirectness                           Other Considerations   GRADE Score                            
  -------------------------------------------------- -------------- ------------- -------------------------------------- ---------------------- ------------- ----- ----- ------------ ----------
  Soft tissue injury                                                                                                                                                                   
   Gray et al^[@bibr25-2325967119831061]^            Yes            No            Flawed measurement                     Not serious            Serious       No    Yes   Very large   High
   Rahr-Wagner et al^[@bibr54-2325967119831061]^     Yes            No            Flawed measurement                     Not serious            Not serious   Yes   Yes   Very large   High
   Agel et al^[@bibr1-2325967119831061]^             No             Yes           None                                   Very serious           Serious       No    No    No           Very low
   Dragoo et al^[@bibr14-2325967119831061]^          No             No            None                                   Serious                Serious       No    No    No           Very low
   Liederbach et al^[@bibr44-2325967119831061]^      No             Yes           None                                   Serious                Serious       No    No    No           Very low
   Ruedl et al^[@bibr58-2325967119831061]^           Yes            Yes           None                                   Serious                Serious       No    No    No           Very low
   Holmes and Lin^[@bibr35-2325967119831061]^        No             Yes           None                                   Very serious           Serious       No    No    Very large   Very low
  Soft tissue laxity                                                                                                                                                                   
   Martineau et al^[@bibr47-2325967119831061]^       Yes            No            None                                   ---                    Not serious   No    Yes   Large        High
   Lee et al^[@bibr41-2325967119831061]^             No             No            None                                   ---                    Not serious   No    No    Large        Low
   Pokorny et al^[@bibr53-2325967119831061]^         Yes            No            None                                   ---                    Not serious   No    No    No           Low
   Shultz et al^[@bibr64-2325967119831061]^          No             No            Confounding risk                       ---                    Not serious   No    Yes   No           Low
   Casey et al^[@bibr10-2325967119831061]^           Yes            Yes           None                                   ---                    Not serious   No    No    No           Very low
   Hicks-Little et al^[@bibr33-2325967119831061]^    No             No            Confounding risk                       ---                    Not serious   No    No    No           Very low
   Lee et al^[@bibr42-2325967119831061]^             No             No            None                                   ---                    Not serious   No    No    No           Very low
   Cammarata and Dhaher^[@bibr9-2325967119831061]^   No             No            None                                   ---                    Not serious   No    No    Large        Low
   Bryant et al^[@bibr8-2325967119831061]^           Yes            No            Confounding risk, flawed measurement   ---                    Not serious   No    No    No           Very low
   Hansen et al^[@bibr27-2325967119831061]^          No             Yes           Flawed measurement                     ---                    Not serious   No    No    No           Very low
  Muscle strength                                                                                                                                                                      
   Wirth and Lohman^[@bibr68-2325967119831061]^      No             No            Confounding risk                       ---                    Not serious   No    No    Very large   Low
   Sarwar et al^[@bibr61-2325967119831061]^          No             No            Confounding risk                       ---                    Not serious   No    No    Large        Very low
   Ekenros et al^[@bibr17-2325967119831061]^         No             Yes           Confounding risk, flawed measurement   ---                    Not serious   No    No    No           Very low
   Petrofsky et al^[@bibr51-2325967119831061]^       No             No            Confounding risk                       ---                    Not serious   No    No    No           Very low
   Elliott et al^[@bibr18-2325967119831061]^         No             No            Confounding risk                       ---                    Not serious   No    No    No           Very low
   Phillips et al^[@bibr52-2325967119831061]^        No             No            Confounding risk                       ---                    Not serious   No    No    No           Very low
   Savage and Clarkson^[@bibr62-2325967119831061]^   No             No            Confounding risk                       ---                    Not serious   No    No    Very large   Low
   Gordon et al^[@bibr24-2325967119831061]^          No             No            Confounding risk                       ---                    Not serious   No    No    No           Very low
   Nichols et al^[@bibr50-2325967119831061]^         Yes            No            None                                   ---                    Not serious   No    No    No           Low
   Minahan et al^[@bibr48-2325967119831061]^         No             No            None                                   ---                    Not serious   No    No    No           Very low
   Casey et al^[@bibr10-2325967119831061]^           Yes            Yes           None                                   ---                    Not serious   No    No    No           Very low
   Allali et al^[@bibr2-2325967119831061]^           No             No            None                                   ---                    Serious       No    Yes   Large        Low

In the risk of bias category, blinding, incomplete reporting, and methodological bias were considered. Studies were marked "serious" for having weaknesses in 1 of these sections and "very serious" for weaknesses in ≥2 sections. Studies in which over 10% of participants withdrew or failed to follow up, or studies that did not report data for all patients for whom data was collected, were downgraded for incomplete reporting. In the methodological bias section, appropriate exclusion criteria and potential confounders were assessed ([Table 2](#table2-2325967119831061){ref-type="table"}). Studies were also downgraded for methodological bias if the exposed and nonexposed groups were not evaluated for the same amount of time, were evaluated differently, or were from different populations.

###### 

Methodological Bias Considerations*^a^*

![](10.1177_2325967119831061-table2)

  Study                                              Age, y           BMI,*^b^* kg/m^2^   Past/Current Pregnancy   Menstrual History   Gynecological History   MSK Injury History   Time on OC   Nonuser Group's History of OC Use   Type and Dose of OC                        Connective Tissue Disease History   Activity Level*^c^*
  -------------------------------------------------- ---------------- ------------------- ------------------------ ------------------- ----------------------- -------------------- ------------ ----------------------------------- ------------------------------------------ ----------------------------------- ---------------------------
  Soft tissue injury                                                                                                                                                                                                                                                                                                
   Gray et al^[@bibr25-2325967119831061]^            15-19            ---                 Not in past year         Regular             None                    ---*^d^*             ≥3 mo        ---                                 Many types                                 ---*^d^*                            ---
   Rahr-Wagner et al^[@bibr54-2325967119831061]^     23.7-24.0*^b^*   ---                 ---*^d^*                 ---                 ---                     None                 1-≥5 y       None                                Low dose                                   ---                                 ---*^d^*
   Agel et al^[@bibr1-2325967119831061]^             ---              ---                 ---                      ---                 ---                     None                 ---          ---                                 Monophasic/triphasic                       ---                                 Competitive
   Dragoo et al^[@bibr14-2325967119831061]^          19.56*^b^*       ---*^d^*            None                     ---*^d^*            ---                     ---                  ---          ---                                 ---                                        ---                                 Competitive
   Liederbach et al^[@bibr44-2325967119831061]^      18-41            19.5-20.5           ---                      ---                 ---                     ---                  ---          ---                                 ---                                        ---                                 Competitive
   Ruedl et al^[@bibr58-2325967119831061]^           14-56            23.2-24.1           ---                      Regular             ---                     ---*^d^*             ---          ---                                 ---                                        ---                                 Recreational
   Holmes and Lin^[@bibr35-2325967119831061]^        35-44            ---                 ---                      ---                 ---                     ---                  ---          ---                                 ---                                        ---                                 ---
  Soft tissue laxity                                                                                                                                                                                                                                                                                                
   Martineau et al^[@bibr47-2325967119831061]^       20.4*^b^*        22.1-23.1           None                     Regular             ---                     None                 ≥3 mo        Not in past 3 mo                    Low-dose monophasic/triphasic              None                                Competitive
   Lee et al^[@bibr41-2325967119831061]^             25.1-25.2*^b^*   21.9-22.3           ---                      Regular             None                    None                 ≥1 y         Not in past 1 y                     Medium- or high-dose monophasic            None                                Recreational
   Pokorny et al^[@bibr53-2325967119831061]^         20-25            ---                 None                     Regular             ---                     None                 ≥3 mo        Not in past 3 mo                    Low-dose monophasic/triphasic              ---                                 Sedentary to recreational
   Shultz et al^[@bibr64-2325967119831061]^          20.7-23.5*^b^*   23.7-24.8           ---                      Regular             None                    ---                  ≥3 mo        ---                                 Medium- or low-dose monophasic/triphasic   None                                Recreational
   Casey et al^[@bibr10-2325967119831061]^           24.0-24.1*^b^*   21.8-22.7           None                     Regular             None                    None                 ≥6 mo        Not in past 6 mo                    Medium- or low-dose monophasic/triphasic   None                                Sedentary to recreational
   Hicks-Little et al^[@bibr33-2325967119831061]^    18-23            ---                 ---                      Regular             ---                     None                 ---          ---                                 ---                                        ---                                 Competitive
   Lee et al^[@bibr42-2325967119831061]^             24.7-25.1*^b^*   21.0-21.6           None                     Regular             ---                     None                 ≥6 mo        ---                                 Medium- or low-dose monophasic/triphasic   ---                                 Sedentary
   Cammarata and Dhaher^[@bibr9-2325967119831061]^   25.0-26.3*^b^*   22.3-22.4           ---                      ---                 ---                     None                 ≥3 mo        ---                                 Low-dose monophasic/triphasic              ---                                 Recreational
   Bryant et al^[@bibr8-2325967119831061]^           28.0-31.9*^b^*   22.1-23.5           ---                      Regular             ---                     None                 ≥1 y         Not in past 1 y                     Low-dose monophasic                        ---                                 Recreational
   Hansen et al^[@bibr27-2325967119831061]^          22-23*^b^*       23-24               None                     Regular             None                    None                 3-10 y       Not in past 5 y                     Low-dose monophasic                        None                                Competitive
  Muscle strength                                                                                                                                                                                                                                                                                                   
   Wirth and Lohman^[@bibr68-2325967119831061]^      18-33            ---                 ---                      Regular             ---                     ---                  ≥6 mo        Not in past 1 y                     Many types                                 ---                                 ---
   Sarwar et al^[@bibr61-2325967119831061]^          20.5-20.7*^b^*   21.2-21.3           ---                      ---                 ---                     ---                  ≥6 mo        ---                                 Medium- or low-dose monophasic             ---                                 Sedentary
   Ekenros et al^[@bibr17-2325967119831061]^         26-27*^b^*       23.1-23.7           ---                      Regular             ---                     None                 1 cycle      Not in past 3 mo*^e^*               Low-dose monophasic                        ---                                 Recreational
   Petrofsky et al^[@bibr51-2325967119831061]^       24-26*^b^*       20.7-22.4                                    Regular             ---                     ---                  ≥3 mo        ---                                 Monophasic                                 ---                                 ---
   Elliott et al^[@bibr18-2325967119831061]^         22-24*^b^*       28.1-28.5           ---                      Regular             ---                     None                 ≥6 mo        ---                                 Medium- or low-dose monophasic             ---                                 Sedentary
   Phillips et al^[@bibr52-2325967119831061]^        21-26*^b^*       22.1-23.8           ---                      Regular             ---                     ---                  ≥3 mo        ---                                 ---                                        ---                                 Competitive
   Savage and Clarkson^[@bibr62-2325967119831061]^   20.8-22.3*^b^*   22.4-23.2           ---                      Regular             ---                     ---                  ≥3 mo        Not in past 3 mo                    ---                                        ---                                 ---
   Gordon et al^[@bibr24-2325967119831061]^          20.3-20.7*^b^*   21.3-22.5           ---                      Regular             ---                     ---                  ≥3 mo        ---                                 Monophasic                                 ---                                 ---
   Nichols et al^[@bibr50-2325967119831061]^         18.7-20.0*^b^*   24.8-25.0           ---                      Regular             ---                     None                 ≥3 mo        Not in past 3 mo                    ---                                        ---                                 Competitive
   Minahan et al^[@bibr48-2325967119831061]^         20-22*^b^*       21.9-22.1           None                     Regular             ---                     ---                  ≥1 y         ---                                 Monophasic                                 ---                                 Recreational
   Casey et al^[@bibr10-2325967119831061]^           24.0-24.1*^b^*   21.8-22.7           None                     Regular             None                    None                 ≥6 mo        Not in past 6 mo                    Medium- or low-dose monophasic/triphasic   None                                Sedentary to recreational
   Allali et al^[@bibr2-2325967119831061]^           54-57*^b^*       28.0-28.5           ---*^d^*                 ---                 None                    None                 ≥2 y         None                                ---                                        ---                                 ---

*^a^*BMI, body mass index; MSK, musculoskeletal; OC, oral contraceptive.

*^b^*Mean value (if reported as a range, the range is bounded by user and nonuser mean values).

*^c^*"Competitive" includes collegiate athletes, elite dancers, competitive rowers, and semiprofessional handball players.

*^d^*Assessed as a covariate but no additional information presented.

*^e^*This study was a crossover design; "not in past 3 mo" refers to the group of participants who began the study with a non--OC use cycle.

The imprecision category was only scored for studies evaluating the relationship between hormonal contraceptive use and soft tissue injuries. Adequately powered trials were designated as having met the optimal information size. Following guidelines in the GRADE handbook,^[@bibr63-2325967119831061]^ articles were listed as having serious imprecision issues if they had fewer than 2000 participants and did not meet optimal information size calculations or if they met optimal information size calculations but their 95% CI included both "no effect" and a 25% difference in relative risk. As recommended in the *British Medical Journal Clinical Evidence* GRADE scoring system, studies were listed as having very serious imprecision issues if they also examined fewer than 200 injury events in addition to the aforementioned criteria.^[@bibr5-2325967119831061]^ In the soft tissue laxity and muscle strength categories, it was discovered that all articles failed to meet the optimal information size. Therefore, all studies in these 2 categories scored "very low" overall according to the GRADEPro software. To distinguish between articles and to score them in a fashion that was useful for quality comparisons, imprecision was not evaluated in the soft tissue laxity and muscle injury/strength categories. Thus, in the GRADEPro software, all studies in the soft tissue laxity and muscle injury/strength categories were scored as having no problems with imprecision.

In the indirectness category, studies were evaluated for applicability to the general population. This review defined the general population as adult premenopausal women with a body mass index (BMI) near the female national average (28.5 kg/m^2^) ^[@bibr22-2325967119831061]^ and with sedentary to low recreational activity levels. For the soft tissue injury category, studies were downgraded if their participants had a BMI considerably above the national average (\>34 kg/m^2^) or had more than a low recreational activity level because increased BMI and activity level increase one's risk of a soft tissue injury.^[@bibr36-2325967119831061],[@bibr39-2325967119831061]^ None of the soft tissue laxity studies were graded down for indirectness, as little information exists on the impact of BMI on soft tissue laxity, and studies have reached contradictory conclusions on the impact of activity level on soft tissue laxity.^[@bibr23-2325967119831061],[@bibr65-2325967119831061],[@bibr67-2325967119831061],[@bibr69-2325967119831061]^ Muscle injury/strength studies were graded down if the outcome measured was not generalizable to the other muscle strength study outcomes or if participants had more than a low recreational activity level because training can influence muscle strength.^[@bibr23-2325967119831061],[@bibr69-2325967119831061]^ In the soft tissue injury section, studies that were downgraded in 1 area were scored as "serious," and those that were downgraded in 2 areas were scored as "very serious." In the muscle injury/strength section, to distinguish quality-of-evidence scores among this body of literature, studies downgraded in both areas were scored as "serious," and no studies were scored as "very serious."

Studies were then evaluated for inconsistency. Within a category (soft tissue injury, laxity, or muscle injury/strength), the overlap of studies' 95% CIs was assessed. An article for which the 95% CI did not overlap with the 95% CIs of the other studies in its category was considered to have serious inconsistencies. However, it was determined that this analysis could only be performed in the soft tissue injury category because the units of the measured outcomes in the soft tissue laxity and muscle injury/strength sections varied greatly between studies. This made it unfeasible to fairly assess for consistency using the 95% CI overlap. Therefore, all studies in the soft tissue laxity and muscle injury/strength sections were listed as having no problems with inconsistency in the GRADEPro software. Additionally, it was found that the 95% CIs for studies in the soft tissue injury category were all overlapping; therefore, all studies were scored "not serious" for inconsistency. Because of this lack of differentiation, the inconsistency scores are not included in [Table 1](#table1-2325967119831061){ref-type="table"}.

In the effect size category, studies were graded up 1 level if they had a *P* value \<.01 and 2 levels for a *P* value \<.001. Furthermore, studies were upgraded 1 level for exhibiting a dose response or showing that an adjustment for confounders increased the effect size. Too few articles were included in this review to evaluate for publication bias.

If authors stratified results or assessed outcomes under multiple conditions, the results presented in this review correspond to the conditions that produced the largest effect size. Additionally, when studies did not present a *P* value, a *P* value was calculated from the provided data using 1-way analysis of variance (see *P* values marked with a citation to endnote *a*). If data were collected at multiple points across the menstrual cycle, to appropriately compare studies that assessed different menstrual cycle phases with those that did not, the reviewers averaged these multiple measurements and presented the calculated means (see *P* values marked with a citation to endnote *b*).

Results {#section2-2325967119831061}
=======

Search Results {#section3-2325967119831061}
--------------

The database searches revealed 703 potentially relevant studies, but ultimately, only 29 studies met inclusion criteria for this review ([Figure 1](#fig1-2325967119831061){ref-type="fig"}). Study characteristics for the included articles can be found in [Table 3](#table3-2325967119831061){ref-type="table"}.

![Workflow of compiled database searches.](10.1177_2325967119831061-fig1){#fig1-2325967119831061}

###### 

Study Characteristics*^a^*

![](10.1177_2325967119831061-table3)

  Study                                              Outcome                                           Methodology: Design (LOE) or Instrumentation   Group 1's Population   Group 2's Population   Effect Size                           *P* Value    Conclusion: OC Use on Outcome   GRADE Score
  -------------------------------------------------- ------------------------------------------------- ---------------------------------------------- ---------------------- ---------------------- ------------------------------------- ------------ ------------------------------- -------------
  Soft tissue injury                                                                                                                                                                                                                                                                   
   Gray et al^[@bibr25-2325967119831061]^            ACL injury rate                                   Cohort (3)                                     5857 injured           17,571 noninjured      OR = 0.82                             \<.0001      Beneficial                      High
   Rahr-Wagner et al^[@bibr54-2325967119831061]^     ACL injury rate                                   Cohort (3)                                     785 injured            8858 noninjured        OR = 0.75                             .0001*^b^*   Beneficial                      High
   Agel et al^[@bibr1-2325967119831061]^             ACL injury rate                                   Case-control (3)                               1124 OC users          2026 nonusers          RR = 0.99                             .49*^b^*     No effect                       Very low
   Dragoo et al^[@bibr14-2325967119831061]^          ACL injury rate                                   Case-control (3)                               63 OC users            65 nonusers            RR = 1.03                             \>.05        No effect                       Very low
   Liederbach et al^[@bibr44-2325967119831061]^      ACL injury rate                                   Case-control (3)                               136 OC users           47 nonusers            RR = 0.35                             .13          No effect                       Very low
   Ruedl et al^[@bibr58-2325967119831061]^           ACL injury rate                                   Cohort (3)                                     93 injured             93 noninjured          OR = 0.98                             \>.05        No effect                       Very low
   Holmes and Lin^[@bibr35-2325967119831061]^        Instance of Achilles tendinopathy                 Case-control (3)                               13 injured             National database      ---*^c^*                              \<.001       Detrimental                     Very low
  Soft tissue laxity                                                                                                                                                                                                                                                                   
   Martineau et al^[@bibr47-2325967119831061]^       Anterior tibial translation                       KT-1000 arthrometer                            42 OC users            36 nonusers            MD = --0.86 mm                        .008         Beneficial                      High
   Lee et al^[@bibr41-2325967119831061]^             Anterior tibial translation                       KT-2000 arthrometer                            15 OC users            25 nonusers            MD = 0.79 mm                          .01          Beneficial                      Low
   Pokorny et al^[@bibr53-2325967119831061]^         Anterior tibial translation                       KT-1000 arthrometer                            30 OC users            25 nonusers            MD = 0.20 mm                          \>.05        No effect                       Low
   Shultz et al^[@bibr64-2325967119831061]^          Anterior tibial translation                       KT-2000 arthrometer                            10 OC users            10 nonusers            MD = 0.15 mm*^b^* ^,*d*^              .83*^b^*     No effect                       Low
   Casey et al^[@bibr10-2325967119831061]^           Anterior tibial translation                       KT-1000 arthrometer                            11 OC users            8 nonusers             MD = 0.10 mm*^b^* ^,*d*^              .88*^b^*     No effect                       Very low
   Hicks-Little et al^[@bibr33-2325967119831061]^    Anterior tibial translation                       KT-1000 arthrometer                            25 OC users            28 nonusers            MD = 0.17 mm                          \>.05        No effect                       Very low
   Lee et al^[@bibr42-2325967119831061]^             Anterior tibial translation                       KT-2000 arthrometer                            9 OC users             10 nonusers            MD = --1.1 mm                         \<.05        Beneficial                      Very low
   Cammarata and Dhaher^[@bibr9-2325967119831061]^   Frontal plane knee stiffness                      Dynamometer chair                              9 OC users             11 nonusers            MD = 0.012 N-m/deg                    \<.05        Detrimental                     Low
   Bryant et al^[@bibr8-2325967119831061]^           Achilles tendon strain (% of resting length)      Ultrasound                                     20 OC users            20 nonusers            MD = --1.20%                          \<.05        Beneficial                      Very low
   Hansen et al^[@bibr27-2325967119831061]^          Patellar tendon laxity                            Ultrasound                                     15 OC users            15 nonusers            MD = 0.30 mm                          .33          No effect                       Very low
  Muscle strength                                                                                                                                                                                                                                                                      
   Wirth and Lohman^[@bibr68-2325967119831061]^      Handgrip (maximum force output)                   Transducer reading                             5 OC users             10 nonusers            MD = --2955 N-s                       \<.05        Detrimental                     Low
   Sarwar et al^[@bibr61-2325967119831061]^          Handgrip (maximum isometric strength)             Dynamometer                                    10 OC users            10 nonusers            MD = --57 N*^b^* ^,*d*^               .002*^b^*    Detrimental                     Very low
   Ekenros et al^[@bibr17-2325967119831061]^         Handgrip (maximum isometric strength)             Dynamometer                                    8 OC users             9 nonusers             MD = --0.30 kg                        .76          No effect                       Very low
   Petrofsky et al^[@bibr51-2325967119831061]^       Handgrip (strength endurance)                     Dynamometer                                    2 OC users             3 nonusers             MD = --68 s*^d^*                      .064*^b^*    No effect                       Very low
   Elliott et al^[@bibr18-2325967119831061]^         First dorsal interosseous isometric strength      Dynamometer                                    14 OC users            7 nonusers             MD = 7.0 N                            \<.05        Beneficial                      Very low
   Phillips et al^[@bibr52-2325967119831061]^        Adductor pollicis maximum voluntary contraction   Transducer reading                             5 OC users             10 nonusers            MD = 12.89 N                          .27*^b^*     No effect                       Very low
   Savage and Clarkson^[@bibr62-2325967119831061]^   Elbow flexor maximum isometric strength           Modified preacher curl bar                     8 OC users             14 nonusers            MD = 75.9 N                           \<.05        Beneficial                      Low
   Gordon et al^[@bibr24-2325967119831061]^          Knee flexor peak torque                           Dynamometer chair                              6 OC users             11 nonusers            MD = 2.15 N-m*^d^*                    .64*^b^*     No effect                       Very low
   Nichols et al^[@bibr50-2325967119831061]^         Knee extensor 10-repetition maximum strength      Leg extension machine                          13 OC users            18 nonusers            MD = 1.0 kg*^b^*                      .50*^b^*     No effect                       Low
   Minahan et al^[@bibr48-2325967119831061]^         Quadriceps peak isometric torque                  Dynamometer chair                              8 OC users             8 nonusers             MD = 6.4 N-m                          .26          No effect                       Very low
   Casey et al^[@bibr10-2325967119831061]^           Rectus femoris muscle stretch reflex              Electromyography recording                     11 OC users            8 nonusers             Median = --0.67 1/N*^b^* ^,*d*,*e*^   \>.05*^b^*   No effect                       Very low
   Allali et al^[@bibr2-2325967119831061]^           Physical performance testing                      Get Up and Go Test                             210 OC users           200 nonusers           MD = --1.84 s                         \<.005       Beneficial                      Low

*^a^*Reported *P* values and effect sizes reflect the relationship exhibiting the most significance. ACL, anterior cruciate ligament; LOE, level of evidence; MD, mean difference; OC, oral contraceptive; OR, odds ratio; RR, relative risk.

*^b^*Effect size or *P* value was not reported; the effect size or *P* value presented in this table was supplied by the authors through email communications or was calculated by the reviewers based on the available figures or raw data.

*^c^*Could not calculate or was an estimate, given the data provided in the text.

*^d^*Measurements were taken at several different points across the menstrual cycle; the reviewers averaged these multiple measurements.

*^e^*Median is the difference in group median values.

Included studies evaluated the effect of OCs on ligament/tendon injuries, ligament/tendon laxity, or muscle strength. None of the included studies examined hormonal intrauterine devices, patches, or implants or other types of soft tissue such as cartilage. Only 2 studies evaluated muscle injuries, making it unfeasible to analyze.^[@bibr48-2325967119831061],[@bibr62-2325967119831061]^ Muscle injury results were therefore not evaluated, although the studies themselves were included in the review because they also examined muscle strength.

Oral Contraceptive Use and Soft Tissue Injuries {#section4-2325967119831061}
-----------------------------------------------

Seven studies examined the effects of OCs on the incidence of soft tissue injuries: 2 concluded that OCs decrease the risk of ACL injuries (*P* \< .0001^[@bibr25-2325967119831061]^ and *P* = .0001^*[a](#fn1-2325967119831061){ref-type="fn"}*,[@bibr54-2325967119831061]^), 4 found OCs to have no effect on ACL injury rates (*P* = .49,^*[a](#fn1-2325967119831061){ref-type="fn"}*,[@bibr1-2325967119831061]^ *P* \> .05,^[@bibr14-2325967119831061]^ *P* = .13,^[@bibr44-2325967119831061]^ and *P* \> .05^[@bibr58-2325967119831061]^), and 1 determined that OCs increase the risk of developing Achilles tendinopathy (a chronic injury) (*P* \< .001)^[@bibr35-2325967119831061]^ ([Table 3](#table3-2325967119831061){ref-type="table"}).

Gray et al^[@bibr25-2325967119831061]^ stratified their results based on age and only obtained significant results in the 15- to 19-year age range (*P* \< .0001); they did not find significant results in their other age groups. Rahr-Wagner et al^[@bibr54-2325967119831061]^ stratified the user group based on the length of time that users had been on OCs, and the largest effect was observed when comparing nonusers to OC users who had been taking OCs for at least 3 years (*P* = .0001*^[a](#fn1-2325967119831061){ref-type="fn"}^*). Similarly, Holmes and Lin,^[@bibr35-2325967119831061]^ who found OCs to increase the risk of developing Achilles tendinopathy, discovered that this relationship was most significant in the 35- to 44-year age range (*P* \< .001), with OC users in other age brackets having less significant or nonsignificant differences in tendinopathy occurrence compared with nonusers.

The 2 studies that found OCs to decrease the risk of ACL injuries (Gray et al^[@bibr25-2325967119831061]^ and Rahr-Wagner et al^[@bibr54-2325967119831061]^) had high quality-of-evidence scores according to the GRADE scoring system. The 5 remaining studies had very low quality-of-evidence scores (see [Table 1](#table1-2325967119831061){ref-type="table"}).^[@bibr1-2325967119831061],[@bibr14-2325967119831061],[@bibr35-2325967119831061],[@bibr44-2325967119831061],[@bibr58-2325967119831061]^ Furthermore, 2 of the studies that evaluated the soft tissue injury risk had features that made it challenging to assess their findings. In Agel et al,^[@bibr1-2325967119831061]^ there were discrepancies between the tables and the text regarding the total number of basketball players and the number of basketball players who were on contraceptives. In addition, Holmes and Lin^[@bibr35-2325967119831061]^ compared their 13 Achilles tendinopathy cases with an unexplained national database, which served as the control representing nontendinopathy cases. The number of patients in the national database was not stated, nor was it established that the database had been evaluated to confirm that it excluded patients who suffered from Achilles tendinopathy.^[@bibr35-2325967119831061]^

Overall, the highest quality evidence currently available suggests that OC use decreases the risk of sustaining an ACL injury.^[@bibr25-2325967119831061],[@bibr54-2325967119831061]^ Notably, this was found to be the case when participants had been on OCs for at least 3 months in 1 study^[@bibr25-2325967119831061]^ and for 1 to 5 years in the other^[@bibr54-2325967119831061]^ (see [Table 2](#table2-2325967119831061){ref-type="table"}). It was not possible to determine any effect of OC dosing, as only 1 of these studies specified that the user group was taking only low-dose formulations,^[@bibr54-2325967119831061]^ while the other included participants using a variety of doses.^[@bibr25-2325967119831061]^ Most lower quality studies did not examine the type of OCs used or the length of time that patients were on contraceptives (see [Table 2](#table2-2325967119831061){ref-type="table"}).^[@bibr14-2325967119831061],[@bibr35-2325967119831061],[@bibr44-2325967119831061],[@bibr58-2325967119831061]^

Oral Contraceptive Use and Soft Tissue Laxity {#section5-2325967119831061}
---------------------------------------------

Ten studies evaluated the relationship between OC use and soft tissue laxity. Of these studies, 4 found OCs to be associated with decreased soft tissue laxity: 3 found OCs to decrease anterior tibial translation (*P* = .008,^[@bibr47-2325967119831061]^ *P* = .01,^[@bibr41-2325967119831061]^ and *P* \< .05^[@bibr42-2325967119831061]^), and 1 determined that OCs decrease Achilles tendon strain (*P* \< .05)^[@bibr8-2325967119831061]^ ([Table 3](#table3-2325967119831061){ref-type="table"}). In contrast, 1 study discovered that OCs increase frontal plane knee laxity (*P* \< .05).^[@bibr9-2325967119831061]^ The remaining 5 studies found no effect of OCs on soft tissue laxity^[@bibr10-2325967119831061],[@bibr27-2325967119831061],[@bibr33-2325967119831061],[@bibr53-2325967119831061],[@bibr64-2325967119831061]^: 4 concluded that OCs do not affect anterior tibial translation (*P* \> .05,^[@bibr53-2325967119831061]^ *P* = .83,^*[b](#fn2-2325967119831061){ref-type="fn"}*,[@bibr64-2325967119831061]^ *P* = .88,^*[b](#fn2-2325967119831061){ref-type="fn"}*,[@bibr10-2325967119831061]^ and *P* \> .05^[@bibr33-2325967119831061]^), and 1 concluded that OCs do not affect patellar tendon laxity (*P* = .33)^[@bibr27-2325967119831061]^ ([Table 3](#table3-2325967119831061){ref-type="table"}).

Three articles assessed the effects of OCs under multiple conditions. Cammarata and Dhaher^[@bibr9-2325967119831061]^ compared frontal plane knee laxity in users of monophasic OCs, users of triphasic OCs, and nonusers at multiple levels of varus and valgus torque. The most significant detrimental effect of OC use was demonstrated in the comparison of triphasic OC users with nonusers at 90% maximum varus torque, with results normalized for body weight and height (*P* \< .05).^[@bibr9-2325967119831061]^ Pokorny et al^[@bibr53-2325967119831061]^ assessed anterior tibial translation at multiple loading levels and found the most significant difference between users and nonusers when evaluating the nondominant knee at a loading level of 89 N (*P* \> .05). Hansen et al^[@bibr27-2325967119831061]^ compared patellar tendon laxity in both the dominant and nondominant knees of OC users and nonusers. The most substantial difference between groups was found in the nondominant knees; however, the effect was still not significant (*P* = .33).^[@bibr27-2325967119831061]^

Of all of the studies examining the effects of OC use on soft tissue laxity, only 1 was given a high quality-of-evidence score. That study concluded that OC use decreased anterior tibial translation.^[@bibr47-2325967119831061]^ Four studies, concluding that OCs decrease frontal plane knee stiffness,^[@bibr9-2325967119831061]^ decrease anterior tibial translation,^[@bibr41-2325967119831061]^ or have no effect on anterior tibial translation,^[@bibr53-2325967119831061],[@bibr64-2325967119831061]^ were graded as low quality. The other 5 studies were scored as very low quality; they concluded that OCs have no effect on soft tissue laxity^[@bibr10-2325967119831061],[@bibr27-2325967119831061],[@bibr33-2325967119831061]^ or decrease laxity^[@bibr8-2325967119831061],[@bibr42-2325967119831061]^ (see [Table 1](#table1-2325967119831061){ref-type="table"}).

The data presentation in 3 studies from the soft tissue laxity category presented difficulties with analysis in this review. In Shultz et al^[@bibr64-2325967119831061]^ and Casey et al,^[@bibr10-2325967119831061]^ raw data were only presented in figures; no means, SDs, or 95% CIs were provided in the text. This is likely because both articles focused on assessing changes in knee laxity over the menstrual cycle, while this review was concerned with average laxity measurements across the menstrual cycle.

Ultimately, the only study in the soft tissue laxity category that earned a high quality-of-evidence score found that OCs decrease ACL laxity.^[@bibr47-2325967119831061]^ Of note, the study participants had been on low-dose combined OCs for at least 3 months (see [Table 2](#table2-2325967119831061){ref-type="table"}).^[@bibr47-2325967119831061]^ The remaining studies received low or very low quality-of-evidence scores and reached a variety of conclusions. In summary, the highest quality research suggested that OC use decreases ACL laxity; however, this finding is limited by the lack of complementary high-quality studies.^[@bibr47-2325967119831061]^

Oral Contraceptive Use and Muscle Strength {#section6-2325967119831061}
------------------------------------------

Twelve studies evaluated the impact of OC use on muscle strength: 3 concluded that OCs increase muscle strength, as measured by first dorsal interosseous isometric strength (*P* \< .05),^[@bibr18-2325967119831061]^ elbow flexor maximum isometric strength (*P* \< .05),^[@bibr62-2325967119831061]^ and physical performance testing (*P* \< .005)^[@bibr2-2325967119831061]^; 2 concluded that OCs decrease muscle strength, as measured by handgrip maximum force output (*P* \< .05)^[@bibr68-2325967119831061]^ and handgrip maximum isometric strength (*P* = .002^*[b](#fn2-2325967119831061){ref-type="fn"}*^)^[@bibr61-2325967119831061]^; and 7 found OCs to have no effect on muscle strength, as measured by handgrip maximum isometric strength (*P* = .76),^[@bibr17-2325967119831061]^ handgrip strength endurance (*P* = .064^*[b](#fn2-2325967119831061){ref-type="fn"}*^),^[@bibr51-2325967119831061]^ adductor pollicis maximum voluntary contraction (*P* = .27*^[a](#fn1-2325967119831061){ref-type="fn"}^*),^[@bibr52-2325967119831061]^ knee extensor 10-repetition maximum strength (*P* = .50*^[a](#fn1-2325967119831061){ref-type="fn"}^*),^[@bibr50-2325967119831061]^ knee flexor peak torque (*P* = .64^*[b](#fn2-2325967119831061){ref-type="fn"}*^),^[@bibr24-2325967119831061]^ quadriceps peak isometric torque (*P* = .26),^[@bibr48-2325967119831061]^ and rectus femoris muscle stretch reflex (*P* \> .05)^*[b](#fn2-2325967119831061){ref-type="fn"}*,[@bibr10-2325967119831061]^ ([Table 3](#table3-2325967119831061){ref-type="table"}).

Gordon et al^[@bibr24-2325967119831061]^ assessed both knee flexors and extensors and stratified their study to measure peak torque at various muscle contraction speeds. The difference between OC users and nonusers was largest for the performance of knee flexors measured at a rotational speed of 240 deg/s; however, this difference was nonsignificant (*P* = .64^*[b](#fn2-2325967119831061){ref-type="fn"}*^).^[@bibr24-2325967119831061]^ Nichols et al^[@bibr50-2325967119831061]^ evaluated several outcomes, including maximum 1-repetition bench press and maximum 10-repetition knee extension strength. This study also evaluated changes in strength parameters over the course of a specialized training program.^[@bibr50-2325967119831061]^ We only considered the baseline measurements in the study of Nichols et al^[@bibr50-2325967119831061]^ because the patients' subsequent participation in the training program made their later performances less comparable with those of the participants in other studies. The largest difference between OC users and nonusers was in the assessment of 10-repetition knee extension strength.^[@bibr50-2325967119831061]^ However, this difference was still nonsignificant (*P* = .50*^[a](#fn1-2325967119831061){ref-type="fn"}^*).^[@bibr50-2325967119831061]^ Elliott et al^[@bibr18-2325967119831061]^ examined the maximum voluntary contraction strength of patients' quadriceps, hamstring, and first dorsal interosseous muscles. The most significant discrepancies between OC users and nonusers were apparent in the first dorsal interosseous strength outcome: users were found to be significantly stronger than their nonuser peers (*P* \< .05).^[@bibr18-2325967119831061]^

Of the 12 studies assessing the influence of OCs on muscle strength, 4 were given low quality-of-evidence scores, and 8 were given very low quality-of-evidence scores. Two of the 4 studies with low scores found that OCs were beneficial for muscle strength (*P* \< .005^[@bibr2-2325967119831061]^ and *P* \< .05^[@bibr62-2325967119831061]^), 1 found that OCs were detrimental (*P* \< .05),^[@bibr68-2325967119831061]^ and 1 found that OCs have no effect (*P* = .50*^[a](#fn1-2325967119831061){ref-type="fn"}^*).^[@bibr50-2325967119831061]^ The remaining 8 studies, all of which were of very low quality, determined that OCs were beneficial (*P* \< .05),^[@bibr18-2325967119831061]^ that OCs were detrimental (*P* = .002^*[b](#fn2-2325967119831061){ref-type="fn"}*^),^[@bibr61-2325967119831061]^ or that there was no association between OC use and muscle strength outcomes (*P* = .76,^[@bibr17-2325967119831061]^ *P* = .064,^*[b](#fn2-2325967119831061){ref-type="fn"}*,[@bibr51-2325967119831061]^ *P* = .27,^*[a](#fn1-2325967119831061){ref-type="fn"}*,[@bibr52-2325967119831061]^ *P* = .64,^*[b](#fn2-2325967119831061){ref-type="fn"}*,[@bibr24-2325967119831061]^ *P* = .26,^[@bibr48-2325967119831061]^ and *P* \> .05^*[b](#fn2-2325967119831061){ref-type="fn"}*,[@bibr10-2325967119831061]^).

In 2 studies that evaluated the influence of OCs on muscle strength, various features of the data presentation complicated the interpretation of the results. Gordon et al^[@bibr24-2325967119831061]^ examined peak torque generated by knee flexors and knee extensors; however, the extensor data reported for the OC user group were identical to the extensor data reported for the nonuser group. Sarwar et al^[@bibr61-2325967119831061]^ did not provide any form of raw numerical data or statistical analysis; a graph displaying handgrip strength versus menstrual cycle phase was the only quantitative information provided. As with the soft tissue laxity section, Sarwar et al^[@bibr61-2325967119831061]^ focused on examining other outcomes in addition to this review's outcomes of interest, possibly explaining the presence of data presentation features that imparted challenges for this review.

In summary, the available research concerning the relationship between OC use and muscle strength is of low or very low quality on the GRADE scoring system. This body of literature presents contradictory conclusions; thus, it remains unclear whether OCs have beneficial,^[@bibr2-2325967119831061],[@bibr18-2325967119831061],[@bibr62-2325967119831061]^ detrimental,^[@bibr61-2325967119831061],[@bibr68-2325967119831061]^ or insignificant effects on muscle strength.^[@bibr10-2325967119831061],[@bibr17-2325967119831061],[@bibr24-2325967119831061],[@bibr48-2325967119831061],[@bibr50-2325967119831061][@bibr51-2325967119831061]--[@bibr52-2325967119831061]^ Ultimately, no conclusions regarding the influence of OC use on muscle strength can be made because of the lack of high-quality literature on the topic.

Discussion {#section7-2325967119831061}
==========

This review analyzed studies evaluating the impact of OC use on soft tissue injuries, soft tissue laxity, and muscle strength. Two conclusions were reached: (1) OC use may act to decrease the rate of ACL injuries, and (2) OC use may act to decrease anterior tibial translation.

The 2 studies that determined that OC use decreases ACL injury rates^[@bibr25-2325967119831061],[@bibr54-2325967119831061]^ earned high quality-of-evidence scores. These studies required their participants to have been on OCs for at least 3 months^[@bibr25-2325967119831061]^ or 1 to 5 years,^[@bibr54-2325967119831061]^ and in 1 study, all of the OC users had been taking low-dose formulations.^[@bibr54-2325967119831061]^ In contrast, all other studies evaluating OC use and ACL injuries had very low quality-of-evidence scores and found OC use to have no effect.^[@bibr1-2325967119831061],[@bibr14-2325967119831061],[@bibr44-2325967119831061],[@bibr58-2325967119831061]^

Another systematic review of the literature by Herzberg et al^[@bibr31-2325967119831061]^ analyzed the relationship between OC use and ACL injuries. Although a less extensive scoring system that only examined the risk of bias on a scale of *good*, *fair*, or *poor* was used and methodological biases were not dissected (see [Table 2](#table2-2325967119831061){ref-type="table"}), the authors reached similar conclusions to the present review. Their results support the findings from the higher quality studies of Rahr-Wagner et al^[@bibr54-2325967119831061]^ and Gray et al^[@bibr25-2325967119831061]^ that OC use may act to decrease ACL injury rates.^[@bibr31-2325967119831061]^ Notably, the authors did not analyze the studies of Dragoo et al^[@bibr14-2325967119831061]^ and Liederbach et al,^[@bibr44-2325967119831061]^ although 3 other studies were alternatively reviewed.^[@bibr4-2325967119831061],[@bibr43-2325967119831061],[@bibr70-2325967119831061]^ These 3 studies examined the influence of OC use on ACL injuries at a particular phase in the menstrual cycle but were found to be of poor quality, making their results difficult to interpret.^[@bibr31-2325967119831061]^

One method by which OCs may reduce the ACL injury risk is through decreasing the production of relaxin. OCs inhibit ovulation, thereby inhibiting the formation of a corpus luteum,^[@bibr18-2325967119831061],[@bibr30-2325967119831061]^ which is the main site of relaxin production.^[@bibr12-2325967119831061]^ Relaxin is a hormone with catabolic properties at the ACL^[@bibr21-2325967119831061],[@bibr38-2325967119831061]^; elevated levels have been associated with increased ACL injury rates in female athletes.^[@bibr12-2325967119831061],[@bibr14-2325967119831061]^ Therefore, in theory, OCs that better inhibit ovulation, such as combined pills compared with progestin-only pills,^[@bibr56-2325967119831061]^ may be better at decreasing the ACL injury risk because increased ovulation suppression should better decrease relaxin levels. However, the only study that compared progestin-only pills with combined pills found no statistically significant difference in ACL injury rates between groups.^[@bibr25-2325967119831061]^

Another method by which OCs may influence ACL injury risk is by inhibiting the hypothalamic-pituitary-gonadal axis, decreasing cyclic fluctuations of estrogen.^[@bibr30-2325967119831061]^ With cycling suppressed, estrogen levels never peak, and endogenous estrogen production decreases.^[@bibr30-2325967119831061]^ Estrogen exhibits catabolic properties at the ACL^[@bibr72-2325967119831061]^ and acts synergistically with relaxin.^[@bibr60-2325967119831061]^ Thus, a decreased ACL injury risk in female patients after OC use is likely the product of a combined decrease in both relaxin and estrogen, and OC regimens that include both estrogen and progestin should theoretically decrease the ACL injury risk more substantially if the estrogen dosage is lower. Of the 2 high-quality studies examining OC use and ACL injuries, 1 study did in fact find that OC use decreased ACL injuries with all patients on low-dose estrogen.^[@bibr54-2325967119831061]^ Although the estrogen dose was not compared, the other study compared monophasic to triphasic users and found monophasic users to have a decreased risk of ACL injuries.^[@bibr25-2325967119831061]^ Triphasic contraceptives contain substantially lower progesterone levels for the earlier parts of the 28-day cycle than monophasic formulas.^[@bibr55-2325967119831061]^ It is possible that the monophasic users had a lower rate of ACL injuries than the triphasic users because they were exposed to more progesterone. Progesterone has in fact been shown to act opposite to estrogen and relaxin at the ACL, decreasing ACL laxity^[@bibr57-2325967119831061]^ and decreasing relaxin-induced collagen degradation.^[@bibr13-2325967119831061],[@bibr29-2325967119831061],[@bibr60-2325967119831061]^ Another study included OC users on monophasic or triphasic OCs but, because of inadequate power, was unable to compare these types of formulations or estrogen dosage and was notably graded as very low quality in this review.^[@bibr1-2325967119831061]^ No other studies examined the influence of OC dosage on ACL injuries (see [Table 2](#table2-2325967119831061){ref-type="table"}).

A similar pattern of conclusions was found in the soft tissue laxity group to the soft tissue injury group. The only study in the soft tissue laxity group that was given a high quality-of-evidence score found that OCs were beneficial.^[@bibr47-2325967119831061]^ Analyzing participants who had taken low-dose combined OCs for at least 3 months, this study concluded that OC use decreased anterior tibial translation.^[@bibr47-2325967119831061]^ In contrast, the other 6 studies evaluating OC use and anterior tibial translation received either low or very low quality-of-evidence scores and concluded that OCs had either beneficial or insignificant effects.^[@bibr10-2325967119831061],[@bibr33-2325967119831061],[@bibr41-2325967119831061],[@bibr42-2325967119831061],[@bibr53-2325967119831061],[@bibr64-2325967119831061]^

As with the high-quality ACL injury studies,^[@bibr25-2325967119831061],[@bibr54-2325967119831061]^ it is likely that the high-quality anterior tibial translation study^[@bibr47-2325967119831061]^ found OCs to decrease anterior tibial translation because of a similar physiological mechanism. Anterior tibial translation is commonly used as a proxy for ACL laxity.^[@bibr10-2325967119831061],[@bibr33-2325967119831061]^ Because of the aforementioned hormonal mechanisms, shifting the metabolic balance away from catabolism with OCs would result in an increase in ACL collagen content. As collagen is the main structural component of the ACL,^[@bibr38-2325967119831061]^ this shift would result in a ligament with greater structural integrity that is less prone to both damage and laxity. Reduced ACL laxity would manifest as decreased anterior tibial translation.

Approximately 35% of American women of reproductive age already use hormonal contraception, with OCs being the most popular nationwide.^[@bibr11-2325967119831061]^ Prescribing OCs would thus be an efficient and easily implementable strategy for reducing the ACL injury prevalence in high-risk female patients.^[@bibr49-2325967119831061]^ This is especially important, given that female patients are up to 8 times more likely than male patients to sustain an ACL tear.^[@bibr3-2325967119831061],[@bibr26-2325967119831061]^ However, it remains poorly understood whether there are particular female patients who may be most responsive to the effects of OCs. Perhaps OCs can significantly decrease the ACL injury risk in nonpregnant female patients with higher than average relaxin levels but not in those with low relaxin levels. Moreover, it is unclear whether different contraceptive formulations may affect ACL injuries differently depending on the route of administration, estrogen or progestin dose, estrogen or progestin type, or administration schedule. The duration of a patient's hormonal contraceptive use may also alter her predisposition to ACL injuries.

Furthermore, this review examined the influence of OC use compared with nonusers, irrespective of the menstrual cycle phase in nonusers. There is currently debate in the literature regarding the influence of menstrual cycle phase on ACL injuries and laxity. Some of the studies included in this review primarily examined OC use compared with controls at certain menstrual cycle phases and found statistically significant differences when looking at menstrual cycle phase but not when looking at the results in aggregate across the entire menstrual cycle.^[@bibr51-2325967119831061],[@bibr64-2325967119831061]^ Furthermore, a 2017 meta-analysis found increased ACL laxity during the ovulatory phase of the menstrual cycle, raising the possibility that the results in this review may be confounded by menstrual cycle phase.^[@bibr31-2325967119831061]^ However, none of the studies included in this meta-analysis were of high quality; all studies were graded as fair quality on a scale of *good*, *fair*, or *poor*.^[@bibr31-2325967119831061]^ This study also systematically reviewed the influence of OC use compared with nonusers on ACL injuries, examining menstrual cycle phase in nonusers, but found all studies examining menstrual cycle phase to be of poor quality.^[@bibr31-2325967119831061]^ Additional higher quality studies are needed to better understand the influence of menstrual cycle phase on soft tissue health and its role as a potential confounder in the literature.

Of the studies evaluating the effects of OC use on muscle strength, 3 found OC use to increase muscle strength,^[@bibr2-2325967119831061],[@bibr18-2325967119831061],[@bibr62-2325967119831061]^ 2 found OC use to decrease muscle strength,^[@bibr61-2325967119831061],[@bibr68-2325967119831061]^ and the remaining 7 studies found OC use to have no effect on muscle strength.^[@bibr10-2325967119831061],[@bibr17-2325967119831061],[@bibr24-2325967119831061],[@bibr48-2325967119831061],[@bibr50-2325967119831061][@bibr51-2325967119831061]--[@bibr52-2325967119831061]^ Because all 12 studies in the muscle strength group received either low or very low quality-of-evidence scores and examined a disparate assortment of muscle types, it was not possible to make definitive conclusions regarding the effects of OCs on muscle strength.

Conclusion {#section8-2325967119831061}
==========

This review ultimately found an association between OC use and a decrease in both ACL injury rates and anterior tibial translation. The clinical applicability of these findings lies in the possibility that OCs could act to decrease female patients' risk of ACL injuries. The literature is, however, limited by the lack of any multicenter randomized controlled trials and also by the low number of high-quality studies. The lack of high-quality studies is particularly evident in the evaluation of OC use as it pertains to muscle strength. Further research is also required to verify the OC-ACL relationship and to better understand the mechanism by which OCs may decrease ACL injury risk.
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The *P* value was not reported; the reviewers calculated this *P* value based on the available data.

The outcome was assessed at various points of the menstrual cycle; the reviewers took the means of these multiple measurements and calculated *P* values using these means.
